HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer.
HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer.
复制标题
DOI：
10.20517/cdr.2021.105
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Höpfner M
中科院分区：
文献类型：
--
作者：
Biersack B;Nitzsche B;Höpfner M
Epigenetic mechanisms play an important role in the development and persistence of cancer, and histone deacetylase (HDAC) inhibitors are promising anticancer drugs targeting epigenetic modes. Efficient anticancer drugs for the treatment of castration-resistant prostate cancer (CRPC) are sought, and approved HDAC inhibitors have shown promising results on the one hand and severe drawbacks on the other hand. Hence, ways to break the drug resistance mechanisms of existing HDAC inhibitors as well as the design of new promising HDAC inhibitors which can overcome the disadvantages of the classic HDAC inhibitors are of great importance. In this work, HDAC inhibitors with the potential to become a mainstay for the treatment of CRPC in the future as well as suitable combination treatments of HDAC inhibitors with other anticancer drugs leading to considerable synergistic effects in treated CRPCs are discussed.
登录
查看更多内容
影响因子：
37.3
作者：
Crea F;Sun L;Mai A;Chiang YT;Farrar WL;Danesi R;Helgason CD
通讯作者：
Helgason CD
影响因子：
5.6
作者：
Gregoretti, IV;Lee, YM;Goodson, HV
通讯作者：
Goodson, HV
影响因子：
5.6
作者：
Goehringer N;Biersack B;Peng Y;Schobert R;Herling M;Ma A;Nitzsche B;Höpfner M
通讯作者：
Höpfner M
DOI：
10.3390/molecules22101551
发表时间：
2017-09-26
期刊：
Molecules (Basel, Switzerland)
影响因子：
--
作者：
Cheng Y;Tian H
通讯作者：
Tian H
影响因子：
2.8
作者：
Armstrong, Kelly;Robson, Craig N.;Leung, Hing Y.
通讯作者：
Leung, Hing Y.